Global Search

Search articles, concepts, and chapters

J GlaucomaJune 20246 citations

Screening of Glaucoma: Consensus and Directions.

Moghimi Sasan, Weinreb Robert N


AI Summary

This review highlights glaucoma screening challenges, finding targeted approaches, telemedicine, genetics, and AI offer cost-effective ways to improve early diagnosis and intervention.

Abstract

Purpose

Glaucoma is a leading public health concern globally. This summary discusses barriers to glaucoma screening and novel strategies for a cost-effective glaucoma screening.

Methods/results: We discuss barriers to glaucoma screening and recent advancements in glaucoma detection and care, including targeted screening approach as well as telemedicine, genetic testing, and artificial intelligence (AI). A major barrier to glaucoma screening is the cost-effectiveness of case finding resulting from the low prevalence of the disease and the complexity of the diagnosis. Targeted-screening, as well as multi-level screening, can reduce the false positive rate and increase the cost-effectiveness of the program. Telemedicine, availability of genetic testing and polygenic risk scores, and AI provide the opportunity for novel glaucoma screening programs in primary care, portable, and home-based settings and will be helpful for lowering the costs, identifying patients in need of urgent treatment and enabling timely diagnosis and early intervention.

Conclusions

Screening of glaucoma is challenging and changing. Recent advancements in digital technology and genetics have led to the development of tools that are promising for novel screening methodologies. Clinical trials are needed to demonstrate the long-term effect of targeted screening on the burden of glaucoma worldwide.


MeSH Terms

HumansArtificial IntelligenceConsensusCost-Benefit AnalysisGenetic TestingGlaucomaIntraocular PressureMass ScreeningTelemedicine

Key Concepts5

A major barrier to glaucoma screening is the cost-effectiveness of case finding, which results from the low prevalence of the disease and the complexity of the diagnosis.

EpidemiologyReviewn=Not applicableCh1Ch10

Targeted-screening and multi-level screening can reduce the false positive rate and increase the cost-effectiveness of glaucoma screening programs.

MethodologyReviewn=Not applicableCh1Ch10

Telemedicine, the availability of genetic testing and polygenic risk scores, and artificial intelligence (AI) offer opportunities for novel glaucoma screening programs in primary care, portable, and home-based settings.

MethodologyReviewn=Not applicableCh1Ch9Ch28

Novel glaucoma screening programs utilizing telemedicine, genetic testing, and artificial intelligence (AI) can help lower costs, identify patients in need of urgent treatment, and enable timely diagnosis and early intervention for glaucoma.

DiagnosisReviewn=Not applicableCh1Ch28

Clinical trials are needed to demonstrate the long-term effect of targeted screening on the burden of glaucoma worldwide.

MethodologyReviewn=Not applicableCh1Ch10

Is this article assigned to the wrong chapter(s)? Let us know.